Revenues (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2021 USD ($) segment	Sep. 30, 2020 USD ($)
Revenue from Contract with Customer [Abstract]
Number of operating segments | segment			1
Revenue from External Customer [Line Items]
Total revenues	$ 6,706	$ 6,423	$ 19,133	$ 18,790
Product sales [Member]
Revenue from External Customer [Line Items]
Total revenues	6,320	6,104	18,026	17,906
Product sales [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	4,558	4,618	12,835	13,325
Product sales [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	1,762	1,486	5,191	4,581
Enbrel® (etanercept) [Member]
Revenue from External Customer [Line Items]
Total revenues	1,289	1,325	3,357	3,724
Enbrel® (etanercept) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	1,263	1,289	3,270	3,619
Enbrel® (etanercept) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	26	36	87	105
Prolia® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total revenues	803	701	2,375	2,014
Prolia® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	530	478	1,569	1,341
Prolia® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	273	223	806	673
Otezla (apremilast) [Member]
Revenue from External Customer [Line Items]
Total revenues	609	538	1,619	1,578
Otezla (apremilast) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	495	439	1,284	1,280
Otezla (apremilast) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	114	99	335	298
XGEVA® (denosumab) [Member]
Revenue from External Customer [Line Items]
Total revenues	517	481	1,473	1,397
XGEVA® (denosumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	372	363	1,061	1,036
XGEVA® (denosumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	145	118	412	361
Neulasta® (pegfilgrastim) [Member]
Revenue from External Customer [Line Items]
Total revenues	415	555	1,383	1,757
Neulasta® (pegfilgrastim) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	360	484	1,215	1,538
Neulasta® (pegfilgrastim) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	55	71	168	219
Aranesp® (darbepoetin alfa) [Member]
Revenue from External Customer [Line Items]
Total revenues	396	384	1,118	1,193
Aranesp® (darbepoetin alfa) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	149	158	409	489
Aranesp® (darbepoetin alfa) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	247	226	709	704
Repatha (evolocumab) [Member]
Revenue from External Customer [Line Items]
Total revenues	272	205	844	634
Repatha (evolocumab) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	139	92	421	331
Repatha (evolocumab) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	133	113	423	303
KYPROLIS® (carfilzomib) [Member]
Revenue from External Customer [Line Items]
Total revenues	293	260	824	793
KYPROLIS® (carfilzomib) [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	198	173	547	527
KYPROLIS® (carfilzomib) [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	95	87	277	266
Other products [Member]
Revenue from External Customer [Line Items]
Total revenues	1,726	1,655	5,033	4,816
Other products [Member] | US [Member]
Revenue from External Customer [Line Items]
Total revenues	1,052	1,142	3,059	3,164
Other products [Member] | ROW [Member]
Revenue from External Customer [Line Items]
Total revenues	674	513	1,974	1,652
Other revenues [Member]
Revenue from External Customer [Line Items]
Total revenues	$ 386	$ 319	$ 1,107	$ 884